(NASDAQ: GRI) Gri Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.24%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 75.03%.
Gri Bio's earnings in 2026 is -$11,956,000.On average, 3 Wall Street analysts forecast GRI's earnings for 2026 to be -$55,810,488, with the lowest GRI earnings forecast at -$107,059,309, and the highest GRI earnings forecast at -$1,335,207. On average, 2 Wall Street analysts forecast GRI's earnings for 2027 to be -$55,460,213, with the lowest GRI earnings forecast at -$53,812,880, and the highest GRI earnings forecast at -$57,656,657.
In 2028, GRI is forecast to generate -$14,711,551 in earnings, with the lowest earnings forecast at -$14,274,574 and the highest earnings forecast at -$15,294,187.